Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Paola Facheris

Dermatologist

IRCCS Humanitas Research Hospital

Research Interests

Explore related searches

Articles (20)

Collaborators (7)

Marco Ardigo

Head Dermatology Oncology

IRCCS Humanitas Research Hospital

Rebecca Favaro

Staff Scientist

Humanitas University

Antonio Costanzo

Full Professor of Dermatology

Humanitas University

Riccardo Borroni

Docenti di ruolo di IIa fascia

Humanitas University

Luciano Ibba

IRCCS Humanitas Research Hospital

LOREDANA FRASCA

Istituto Superiore di Sanità

Mario Valenti

Humanitas University

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Paola Facheris

Research Interests

Explore related searches

Articles (20)

Collaborators (7)

Marco Ardigo

Rebecca Favaro

Antonio Costanzo

Riccardo Borroni

Luciano Ibba

LOREDANA FRASCA

Mario Valenti

Make your next move.

Paola Facheris

Research Interests

Explore related searches

Articles (20)

Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study

Targeting TYK2 in Cutaneous Autoimmunity: Deucravacitinib-Induced Remission of Discoid Lupus and Psoriasis with Supportive Confocal Microscopy Findings

Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study

JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study

Dose Adjustment of JAK Inhibitors for the Management of Moderate-to-Severe Atopic Dermatitis: A Single-Centre Retrospective Study

Reply to Hagino et al.: ‘Importance of Upadacitinib dose escalation prior to switch to lebrikizumab’

The nature of the post-translational modifications of the autoantigen LL37 influences the autoreactive T-helper cell phenotype in psoriasis

Risankizumab differentially modulates circulating T-cell populations in psoriasis according to autoreactivity status

OX40 and Regulatory Marker Alterations in Lesional and Non‐Lesional Keloid Tissues

Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study

New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review

Potential role of leptin in Janus kinase 2 inhibitor-associated weight gain: A monocentric retrospective study

Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients

Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo

Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study

Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis

Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study

Atypical facial pustular folliculitis by <i>Klebsiella pneumoniae</i>: a case report

Collaborators (7)

Marco Ardigo

Rebecca Favaro

Antonio Costanzo

Riccardo Borroni

Luciano Ibba

LOREDANA FRASCA

Mario Valenti

Make your next move.